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The patient was a 58-year-old male nonsmoker diagnosed with 
advanced adenocarcinoma associated with malignant pleural 
effusion and bone metastases. After the failure of first-line 
platinum-based chemotherapy, the known lesions progressed 
and liver metastases newly developed. A fluorescence in situ 
hybridization analysis of the biopsied sample of the pleural 
disseminated lesions identified the ALK rearrangement, and 
crizotinib was therefore administered. Although a partial 
response was obtained, lumbar metastases were observed 
approximately 28 months after the administration of crizotinib, 
and treatment with ceritinib was initiated. Although a partial 
response was obtained (Fig. 1A and B), computed tomogra-
phy and positron emission tomography/computed tomography 
performed approximately 2 years after the start of ceritinib 
thereby demonstrated relapse of the hepatic metastases (Fig. 
1C and D), and a subsequent rebiopsy of the hepatic lesions 
was performed. Consequently, the biopsy sample of the pleu-
ral dissemination obtained before crizotinib treatment showed 
no secondary mutations in the ALK gene (Fig. 2A), whereas 
reverse transcription polymerase chain reaction of the rebi-
opsy sample identified a previously unidentified secondary 
mutation of the ALK gene at codon 1123 (Fig. 2B; G1123S). 
Alectinib was thus administered, and a prompt and dramatic 
response in the hepatic lesions was observed approximately 6 
weeks after the initiation of alectinib (Fig. 2C).
Secondary mutations in the ALK gene are consid-
ered to be the most frequent mechanisms mediating resis-
tance to ALK inhibitors. Although many ALK secondary 
mutations have been identified to confer resistance to 
crizotinib, a few mutations in the ALK gene conferring 
resistance to alectinib and ceritinib have also been found, 
i.e., G1202R, I1171T/N/S, and V1180L for alectinib 
and G1202R and F1174C/V for ceritinib.1–5 With regard 
to mutations at codon 1123, in vitro analyses have dem-
onstrated that a human-derived neuroblastoma cell line, 
SH-SY5Y, expressing G1123S or G1123D shows resis-
tance to TAE684, an ALK inhibitor.6 Such mutations at 
codon 1123, which is located in the glycine-rich loop, 
seem to sterically block adenosine triphosphate binding 
and/or alter the dynamics of the glycine-rich loop, result-
ing in perturbation of the interactions with ALK inhibitors, 
which require a particular conformation of the loop for 
binding.6 However, there are no previous reports showing 
that G1123S and G1123D confer resistance to ceritinib 
in ALK+ lung cancer patients and/or lung cancer cell line 
models. Hence, this is the first report to identify an ALK 
G1123S mutation in a patient with ALK+ non–small-cell 
lung cancer acquiring resistance to ceritinib.
Furthermore, it is intriguing that treatment with alec-
tinib was able to overcome the resistance to ceritinib mediated 
by G1123S in this case, though the duration of the response 
achieved with alectinib is unknown at present. In addition 
to evidences demonstrating the sequential administration of 
next-generation ALK inhibitors after the failure of crizotinib 
to be effective, the use of ceritinib was recently reported to 
overcome alectinib resistance mediated by I1171T.4 However, 
it remains unreported whether the administration of alectinib 
can overcome ceritinib resistance. The present report showed 
that therapy with alectinib may overcome ceritinib resistance 
through the G1123S mutation, a novel and effective sequential 
use of ALK inhibitors.
In summary, the G1123S mutation was identified in 
a patient with ALK+ non–small-cell lung cancer exhibiting 
resistance to ceritinib. This report underlines both the pos-
sible presence of a novel ALK mutation mediating ceritinib 
resistance and the new application of sequential therapy with 
ALK inhibitors, i.e., ceritinib followed by alectinib.
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FIGURE 1.  Computed tomography scans showed metastatic liver metastases (A) before and (B) approximately 5 months after 
the administration of ceritinib. C and D, Computed tomography and positron emission tomography/computed tomography 
indicated exacerbation of the hepatic metastases. Scale bar: 1 cm.
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FIGURE 2.  Direct sequencing with capillary electrophoresis of biopsy samples obtained from the liver metastases (A) before and 
(B) after the administration of ceritinib using an ABI PRISM 310 Genetic analyzer. C, Computed tomography scans performed 6 
weeks after the administration of alectinib showing the rapid response of the hepatic metastases to alectinib. Scale bar: 1 cm.
